TickerTalks
Browse all tickers →
TickerTalks›$DNLI
DNDNLI

Denali Therapeutics Inc.

$DNLI·$3.9B·Biotechnology·Healthcare
$24.00-2.7%YTD+45.1%1Y+53.4%
Mentions · last 7 days
2026-08-20: 5 posts2026-08-21: 0 posts2026-08-22: 2 posts2026-08-23: 1 posts19-22%
Price updated 1d ago·X counts updated 6d ago
DNDNLI
$DNLIDenali Therapeutics Inc.
$24.00-2.72%19 posts-22%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $DNLI, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventStalledAI verdict · as of 2026-08-29

The move has stalled — likely just drifts unless something new shows up.

Neurodegeneration biotech: LRRK2 Parkinson's Phase 2b failed with Biogen, but AVLAYAH commercial + BBB platform remains.

Denali Therapeutics is a $3.94B South-SF neurodegeneration biotech (blood-brain-barrier "TV" platform, Hunter/Sanfilippo enzyme-replacement, LRRK2 program) at $24.00 — +45% YTD, +53% t12m to 78% of its 52w range. But the underlying picture is contested by a fresh Phase 2b failure.

  • Q2 EPS -$0.68 vs -$0.51 (-33% miss), Q1 -$0.69 vs -$0.73 (+5% beat) — burn is deep and Q2 miss reflects trial spend intensification.
  • Cash economics: revenue zero (both quarters), FCF yield -12.5%, D/E 0.04 (clean balance sheet — that's the pipeline company profile), EV/EBITDA -5.7.
  • Analyst path FY26 rev $35M / EPS -$2.42 → FY27 $106M / -$2.44 — Street models AVLAYAH (Hunter Syndrome enzyme-replacement) commercial launch driving revenue.
  • Recent Rare Pediatric Disease PRV sale on July 27 for undisclosed cash proceeds — a discrete non-dilutive cash inflow event.
  • BlackRock initiated new position — institutional support present.
  • Insider signal is trivial: Watts G-Gift, Schuth S-Sale $72K — no meaningful cluster.
  • Sentiment (6 posts): decisively bearish — Phase 2b LUMA study of BIIB122 (DNL151) failed both primary and secondary endpoints in early-stage Parkinson's; Biogen and Denali discontinuing idiopathic-Parkinson's development of the LRRK2 inhibitor. That's a major pipeline setback.

Read as a neurodegeneration biotech whose AVLAYAH commercial-story is the durable thesis but whose LRRK2/Parkinson's Phase 2b failure with Biogen is a real pipeline setback; the debated question is whether AVLAYAH launch execution + BBB platform value hold up the multiple after the LRRK2 loss, or whether Q3 revenues confirm AVLAYAH doesn't offset the setback.

Agrees with X sentimentX is decisively bearish on the LUMA Phase 2b failure and discontinuation; verdict aligns while framing AVLAYAH as the remaining durable thesis.

What to watch: AVLAYAH commercial launch metrics, PRV sale gross proceeds detail, BBB platform-partnership updates on the Nov 5 print.

On the calendar: 2026-11-05 Q3 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bearish sentiment6 posts analyzed · as of 2026-05-27

Denali Therapeutics posts sharply bearish on the Phase 2b LUMA study of BIIB122 (DNL151) failing both primary and secondary endpoints in early-stage Parkinson's. Biogen and Denali will discontinue idiopathic-Parkinson's development of the LRRK2 inhibitor, anchoring the dominant bearish catalyst that pushed AI portfolios into cash.

Read the AI verdict + X sentiment for $DNLI

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops CNS drugs using a blood-brain barrier transport technology platform for neurodegenerative diseases.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $DNLI.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $DNLI

Partial — Develops CNS drugs using a blood-brain barrier transport technology platform for neurodegenerative diseases; partial earnings exposure to biotechnology demand dynamics through its product portfolio.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+51.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-7.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-46.9%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-12.6%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-52.2%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$-0.68$-0.51-32.5%
Q1 2026May 7, 2026$-0.69$-0.73+5.5%
Q4 2025Feb 26, 2026$-0.73$-0.75+2.7%
Q3 2025Nov 6, 2025$-0.74$-0.76+2.6%
Next earningsThu, Nov 5·consensus EPS $-0.42

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.69$-133.7M
Q4 FY25$0———$-0.73$-100.1M
Q3 FY25$0———$-0.74$-105.9M
Q2 FY25$0———$-0.72$-79.6M

Forward consensus

5-year forecast · up to 16 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$35.0M$3.2M – $178.3M-$2.42-$2.76 – -$1.5615
FY27$106.4M$38.5M – $181.5M-$2.44-$2.84 – -$2.0416
FY28$266.8M$59.7M – $811.3M-$1.84-$3.16 – $0.2716
FY29$439.5M$114.7M – $1.3B-$0.98-$3.53 – -$0.0415
FY30$754.4M$196.8M – $2.3B$0.35$0.01 – $1.2715

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.78%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-2.3%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+15.9%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 148.7M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.5% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.005-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 11Alexander O. SchuthCOFO and Secretary2.9K sh$72K
+ 9 other (8 awards · 1 gift) in window

See when $DNLI insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KAcquisition completedJul 288-K — Item 2.01: Acquisition completed
AI summary

Denali Therapeutics Inc. (DNLI) completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) to an unnamed large pharmaceutical company on July 27, 2026, receiving gross proceeds of $195.0 million. The PRV was awarded when AVLAYAH (tividenofusp alfa) received FDA approval for Hunter syndrome (MPS II) in March 2026; the sale was made pursuant to a PRV Transfer Agreement dated June 12, 2026. This is a materially accretive non-dilutive cash infusion of $195M for a clinical-stage biotech, meaningfully extending its cash runway.

8-KMaterial agreementJun 188-K — Item 1.01: Material agreement · Item 7.01: Press release / Reg FD
AI summary

Denali Therapeutics (DNLI) entered an agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $195 million in cash. The PRV was awarded upon FDA approval in March 2026 of AVLAYAH (tividenofusp alfa) for Hunter syndrome (MPS II). The transaction is subject to HSR antitrust clearance. The $195M PRV sale represents material non-dilutive cash proceeds with no operational impact on Denali's pipeline.

8-KShareholder voteJun 48-K — Item 5.07: Shareholder vote
AI summary

Denali Therapeutics Inc. (DNLI) disclosed the results of its annual meeting of shareholders in an 8-K filing under Item 5.07. Shareholders voted on an advisory say-on-pay resolution, ratification of the independent auditor. All management-sponsored proposals were approved by majority shareholder vote. Annual meeting results are a routine disclosure that confirms shareholder ratification of the board's composition and compensation practices.

8-KPress release / Reg FDMay 228-K — Item 7.01: Press release / Reg FD
AI summary

Denali Therapeutics Inc. (DNLI) filed an 8-K on May 21, 2026 under Item 7.01 (Regulation FD Disclosure), furnishing an investor presentation or data release. Denali is a South San Francisco-based clinical-stage neuroscience biopharmaceutical company listed on Nasdaq. Reg FD disclosures for biotech companies typically contain pipeline updates or conference presentations; the content may be material for investors tracking Denali's neurodegenerative disease programs.

3/ANew insider — initial holdingsApr 213/A
AI summary

Form filed by More than One Reporting Person Table I - Non-De filed a Form 3/A (amended) for DNLI on 2026-04-21, initiating required Section 16 reporting. Role: of Reporting Person. Form 3 is a mandatory administrative filing upon first becoming an insider or 10%+ holder; it does not reflect a purchase or sale event.

3New insider — initial holdingsApr 203
AI summary

Form filed by More than One Reporting Person Table I - Non-De filed a Form 3 (initial ownership statement) for DNLI on 2026-04-20, initiating required Section 16 reporting. Role: of Reporting Person. Beneficial ownership covers 2029 shares. Form 3 is a mandatory administrative filing upon first becoming an insider or 10%+ holder; it does not reflect a purchase or sale event.

8-KAgreement terminatedApr 38-K — Item 1.02: Agreement terminated
AI summary

DNLI filed an 8-K (other items) dated 2026-04-03. 0001714899 FALSE 0001714899 2026-04-03 2026-04-03 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2026 Denali Therapeutics Inc. Strategic partnership or contract announcement; watch for revenue materiality.

8-KMaterial debt obligationMar 318-K — Item 2.03: Material debt obligation · Item 7.01: Press release / Reg FD
AI summary

DNLI filed an 8-K Item 7.01 (Reg FD) disclosure dated 2026-03-31. Reg FD disclosures make material information simultaneously available to all investors; content may include guidance updates, strategic plans, or preliminary results.

+ 13 other (5 13Gs · 2 10-Qs · 2 earnings 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

BlackRock Inc. Takes Position in Denali Therapeutics Inc. $DNLIdefenseworld.net·4d agoDNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock?zacks.com·10d agoDenali Therapeutics: Bullish On Avlayah And Their Prospectsseekingalpha.com·11d agoHead to Head Comparison: Denali Therapeutics (NASDAQ:DNLI) versus Humacyte (NASDAQ:HUMA)defenseworld.net·11d agoDenali Therapeutics: AVLAYAH Converts A Platform Story Into A Commercial Oneseekingalpha.com·17d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALT$AURA$IOVA$NWBO$SLS$AMLX$ABCL
Voices on X · last 7 days

No standout posts about $DNLI on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport